國家衛生研究院 NHRI:Item 3990099045/13302
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 906449      Online Users : 974
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/13302


    Title: Beta-glucan therapy converts the inhibition of myeloid-derived suppressor cells in oral cancer patients
    Other Titles: β-glucan therapy converts the inhibition of myeloid-derived suppressor cells in oral cancer patients
    Authors: Lo, YW;Lee, AY;Liu, YC;Ko, HH;Peng, HH;Lee, HC;Pan, PY;Chiang, CP;Cheng, SJ
    Contributors: National Institute of Cancer Research
    Abstract: OBJECTIVES: The myeloid-derived suppressor cells (MDSCs) frequently have a high expansion in cancer patients. This research explored whether administration of β-glucan could increase anti-tumor immunity in oral squamous cell carcinoma (OSCC) patients. MATERIALS AND METHODS: This study evaluated the MDSC level of circulating blood as CD33(+) /CD11b(+) /HLA-DR(-/low) by flow cytometry in 30 healthy donors (HDs, group I), in 48 oral squamous cell carcinoma (OSCC) patients before and after 14-day pre-operative administration of β-glucan (group II), and in 52 OSCC patients without taking β-glucan (group III). RESULTS: A significantly higher mean MDSC level was observed in 100 OSCC patients than in 30 HDs (p < 0.001). There was a significant reduction of the mean MDSC level in group II patients after taking β-glucan (p < 0.001). Moreover, we discovered a significantly higher recurrence-free survival (RFS) in group II than in group III patients (p = 0.026). Finally, the multivariate Cox regression further identified the MDSC level ≤ 1% and administration of β-glucan as more favorable prognostic factors for OSCC patients. CONCLUSION: Preoperative administration of β-glucan can augment anti-tumor immunity and increase RFS rate via subversion of suppressive function of MDSC in OSCC patients.
    Date: 2022-09
    Relation: Oral Diseases. 2022 Sep;28(6):1484-149.
    Link to: http://dx.doi.org/10.1111/odi.13827
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1354-523X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000628452300001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85102475600
    Appears in Collections:[Alan Yueh-Luen Lee] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB33655573.pdf2321KbAdobe PDF314View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback